Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab

• Ferdows Ather ,

  ¶These authors are joint first authors on this work.

  Affiliation Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Habib Hamidi ,

  * E-mail: hhamidi@mednet.ucla.edu

  ¶These authors are joint first authors on this work.

  Affiliation Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Marlena S. Fejzo,

  Affiliation Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Stephen Letrent,

  Affiliation Clinical Development and Medical Affairs, Pfizer Oncology, San Diego, California, United States of America

  ⨯
• Richard S. Finn,

  Affiliation Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Fairooz Kabbinavar,

  Affiliation Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Christian Head,

  Affiliation Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Steven G. Wong

  Affiliation Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯